Quince Therapeutics
QNCX
38 hedge funds and large institutions have $13.5M invested in Quince Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
8,250% more call options, than puts
Call options by funds: $167K | Put options by funds: $2K
13% more capital invested
Capital invested by funds: $12M → $13.5M (+$1.53M)
0.02% more ownership
Funds ownership: 0.11% → 0.12% (+0.02%)
10% less funds holding
Funds holding: 42 → 38 (-4)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.2M |
| 2 |
KAM
Knightsbridge Asset Management
Newport Beach,
California
|
+$356K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$230K |
| 4 |
Renaissance Technologies
New York
|
+$91.8K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
+$83.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$333K |
| 2 |
Millennium Management
New York
|
-$290K |
| 3 |
Two Sigma Investments
New York
|
-$89.3K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$85.6K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$73K |
QNCX Hedge Fund Activity: Q2 2023 in Review
38 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2023, worth a combined $13.5M — up 13% from $12M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of QNCX and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $2.2M. The largest seller was Two Sigma Advisers, cutting an estimated $333K.
- 38 institutional investors held Quince Therapeutics (QNCX) as of Q2 2023, down from 42 in Q1 2023.
- Funds reported $13.5M of Quince Therapeutics stock for Q2 2023, up 13% quarter-over-quarter.
- 5 funds opened new Quince Therapeutics positions in Q2 2023 and 8 closed out, a net change of -3 holders.
- The largest Quince Therapeutics buyer in Q2 2023 was BML Capital Management, an estimated $2.2M added.
- The largest Quince Therapeutics seller in Q2 2023 was Two Sigma Advisers, an estimated $333K sold.
Based on aggregated 13F filings for Q2 2023.